Press coverage about Perrigo (NYSE:PRGO) has been trending positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Perrigo earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.3344835761862 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of equities analysts have recently issued reports on PRGO shares. BidaskClub downgraded Perrigo from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the company a “buy” rating in a report on Friday, October 20th. Deutsche Bank increased their price objective on shares of Perrigo from $88.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, September 14th. Canaccord Genuity reiterated a “buy” rating and issued a $100.00 price objective (up previously from $88.00) on shares of Perrigo in a report on Wednesday, September 13th. Finally, Jefferies Group set a $71.00 price objective on shares of Perrigo and gave the company a “hold” rating in a report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. Perrigo presently has a consensus rating of “Hold” and a consensus target price of $92.13.

Shares of Perrigo (PRGO) traded up $2.46 during mid-day trading on Friday, hitting $86.50. 2,098,800 shares of the stock traded hands, compared to its average volume of 1,687,734. The stock has a market capitalization of $12,115.12, a P/E ratio of 17.56, a PEG ratio of 1.83 and a beta of 0.70. The company has a quick ratio of 1.24, a current ratio of 1.72 and a debt-to-equity ratio of 0.54. Perrigo has a fifty-two week low of $63.68 and a fifty-two week high of $91.73.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.28. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.65 earnings per share. research analysts forecast that Perrigo will post 4.88 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 19th. Investors of record on Friday, December 1st will be issued a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.74%. Perrigo’s dividend payout ratio (DPR) is presently -6.99%.

In related news, EVP John Wesolowski sold 450 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $83.09, for a total value of $37,390.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 1,051 shares of company stock valued at $89,810 in the last quarter. 6.90% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Insider Buying and Selling by Quarter for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with's FREE daily email newsletter.